Scientists at the Wellcome Sanger Institute have discovered that CRISPR/Cas9 gene editing can cause greater genetic damage in cells than was previously thought. These results create safety implications for gene therapies using CRISPR/Cas9 in the future as the unexpected damage could lead to dangerous changes in some cells.
Reported today (16 July 2018) in the journal Nature Biotechnology, the study also revealed that standard tests for detecting DNA changes miss finding this genetic damage, and that caution and specific testing will be required for any potential gene therapies.
CRISPR/Cas9 is one of the newest genome editing tools. It can alter sections of DNA in cells by cutting at specific points and introducing changes at that location. Already extensively used in scientific research, CRISPR/Cas9 has also been seen as a promising way to create potential genome editing treatments for diseases such as HIV, cancer or sickle cell disease. Such therapeutics could inactivate a disease-causing gene, or correct a genetic mutation. However, any potential treatments would have to prove that they were safe.
Previous research had not shown many unforeseen mutations from CRISPR/Cas9 in the DNA at the genome editing target site. To investigate this further the researchers carried out a full systematic study in both mouse and human cells and discovered that CRISPR/Cas9 frequently caused extensive mutations, but at a greater distance from the target site.
The researchers found many of the cells had large genetic rearrangements such as DNA deletions and insertions. These could lead to important genes being switched on or off, which could have major implications for CRISPR/Cas9 use in therapies. In addition, some of these changes were too far away from the target site to be seen with standard genotyping methods.
“This is the first systematic assessment of unexpected events resulting from CRISPR/Cas9 editing in therapeutically relevant cells, and we found that changes in the DNA have been seriously underestimated before now. It is important that anyone thinking of using this technology for gene therapy proceeds with caution, and looks very carefully to check for possible harmful effects.”
Professor Allan Bradley, corresponding author on the study from the Wellcome Sanger Institute
“My initial experiment used CRISPR/Cas9 as a tool to study gene activity, however it became clear that something unexpected was happening. Once we realised the extent of the genetic rearrangements we studied it systematically, looking at different genes and different therapeutically relevant cell lines, and showed that the CRISPR/Cas9 effects held true.”
Michael Kosicki, the first author from the Wellcome Sanger Institute
The work has implications for how CRISPR/Cas9 is used therapeutically and is likely to re-spark researchers’ interest in finding alternatives to the standard CRISPR/Cas9 method for gene editing.
“This study is the first to assess the repertoire of genomic damage arising at a CRISPR/Cas9 cleavage site. While it is not known if genomic sites in other cell lines will be affected in the same way, this study shows that further research and specific testing is needed before CRISPR/Cas9 is used clinically.”
Professor Maria Jasin, an independent researcher from Memorial Slone Kettering Cancer Centre, New York, who was not involved in the study
The Latest on: CRISPR/Cas9
via Google News
The Latest on: CRISPR/Cas9
- ERS Genomics Limited: Vivlion GmbH Signs Worldwide License Agreement With ERS Genomics for CRISPR/Cas9 Patent Portfolioon December 1, 2020 at 1:12 am
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Vivlion GmbH, a startup company providi ...
- Vivlion GmbH Signs Worldwide License Agreement With ERS Genomics for CRISPR/Cas9 Patent Portfolioon December 1, 2020 at 1:04 am
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Vivlion GmbH, a startup company ...
- Emmanuelle Charpentier And Jennifer Doudna Sharpened Mother Nature’s Genetic Scissors And Won The Nobel For Iton November 27, 2020 at 4:00 pm
But as it turns out, CRISPR/Cas9 gene editing is a completely natural function in which bacteria catalogs its interactions with viruses by taking a snippet of the virus’ genetic material and ...
- COVID-19's impact Global CRISPR Cas9 Market 2020 Production, Revenue, Price and Gross Margin Analysis with Forecasts to 2025on November 26, 2020 at 12:19 pm
Nov 26, 2020 (The Expresswire) -- Global “CRISPR Cas9 market” competitive landscape provides particulars and data information by players. The report offers complete analysis and accurate ...
- Metal-Organic Frameworks Successfully Deliver CRISPR/Cas9 Into Human Cancer Cellson November 23, 2020 at 2:51 am
A new high-resolution cryo-electron microscopy study shows how the Chinese tarantula stinger quickly locks voltage sensors on sodium channels, the tiny pores on cell membranes that create electrical ...
- Revolutionary CRISPR-based genome editing system treatment destroys cancer cellson November 22, 2020 at 5:12 pm
CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Science Advances , 2020; 6 (47): eabc9450 DOI: 10.1126/sciadv.abc9450 Cite This Page : ...
- Metal-Organic Frameworks Successfully Deliver CRISPR/Cas9 Into Human Cancer Cellson November 22, 2020 at 4:00 pm
Researchers used metal-organic frameworks (MOFs) enhanced with a green tea phytochemical coating to target human prostate cancer cells for the first time.
- This Company's New Approach Could Slash Gilead's Profit From HIV Drugson November 22, 2020 at 3:32 am
A small private biotech has data showing that its use of CRISPR-Cas9 gene editing could potentially eliminate the need for patients -- and those at risk -- to take HIV drugs for the rest of their ...
- Super-porous material transports cancer-killing CRISPR inside cellson November 21, 2020 at 4:00 pm
The CRISPR/Cas9 gene-editing tool has shown promise in treating a wide range of diseases, but getting it into cells in the first place can be challenging. Now, researchers in Australia have ...
via Bing News